Aktienanalyse zu Electra Therapeutics, Inc. Common stock (ETRA)

$8.980

+0.485 (+5.40%)Zum Schluss

Loading chart…

Hoch: 9.210
Eröffnung: 8.360
Volumengewichteter Durchschnittskurs: 8.85
Volumen: 177.30K
Marktkap.: —
Tief: 8.360
Umsatz: 1.57M
EV/EBITDA, TTM: 0.00

Electra Therapeutics Inc is a United States-based clinical- stage biotechnology company. The Company is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Its ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and precisely depletes pathological immune cells.

electra-therapeutics.com

KI-Analyse of Electra Therapeutics, Inc. Common stock (ETRA)

Verkaufen

Electra Therapeutics, Inc. is not a good buy right now due to significant declines in its stock price and lack of positive financial indicators. The stock has fallen 41.93% year-to-date and 24.59% over the last 20 days, indicating a persistent downward trend. Furthermore, the company has a price-to-book ratio of -21.69, which suggests severe financial distress. Without any earnings or positive analyst ratings to support a recovery, the risks outweigh potential rewards.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Electra Therapeutics, Inc. Common stock (ETRA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von .

Erwartetes KGV

5J-Durchschnitt P/E

Aktuelles P/E

0.00

Erwartetes EV/EBITDA

5J-Durchschnitt EV/EBITDA

Aktuelles EV/EBITDA

0.00

Erwartetes KUV

5J-Durchschnitt P/S

Aktuelles P/S

0.00

Event-Zeitleiste

2026-09-21 (ET)